These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 22980964)

  • 1. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention.
    MacHaalany J; Abdelaal E; Bataille Y; Plourde G; Duranleau-Gagnon P; Larose É; Déry JP; Barbeau G; Rinfret S; Rodés-Cabau J; De Larochellière R; Roy L; Costerousse O; Bertrand OF
    Am J Cardiol; 2012 Dec; 110(12):1742-8. PubMed ID: 22980964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
    Abtahian F; Waldo S; Jang IK
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
    Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
    Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
    JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
    Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
    Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
    Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
    Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalirudin during primary PCI in acute myocardial infarction.
    Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
    N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
    Liang Z; Li Y; Wang J; Wang D; Wang S; Ma L; Liu H; Yang L; Stone GW; Han Y
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():608-15. PubMed ID: 26762481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
    Sardi GL; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
    Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
    Bangalore S; Cohen DJ; Kleiman NS; Regev-Beinart T; Rao SV; Pencina MJ; Mauri L;
    Circ Cardiovasc Interv; 2011 Oct; 4(5):463-73. PubMed ID: 21972401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention.
    Barria Perez AE; Rao SV; Jolly SJ; Pancholy SB; Plourde G; Rimac G; Poirier Y; Costerousse O; Bertrand OF
    Am J Cardiol; 2016 Apr; 117(8):1256-66. PubMed ID: 26899489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A
    J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.